| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/IJC.20129 |
| P8608 | Fatcat ID | release_r4zvs6e6aveq3nadhylw2kpvwu |
| P698 | PubMed publication ID | 15122578 |
| P5875 | ResearchGate publication ID | 8582094 |
| P50 | author | Akseli Hemminki | Q26920981 |
| Anna Kanerva | Q64398934 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Adenoviridae | Q193447 |
| gene therapy | Q213901 | ||
| cancer gene therapy | Q124350675 | ||
| P304 | page(s) | 475-480 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Modified adenoviruses for cancer gene therapy | |
| P478 | volume | 110 |
| Q36387946 | A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy |
| Q36158701 | A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. |
| Q49963933 | A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy |
| Q44607522 | A one-step ligation system for rapid generation of armed, conditionally-replicating adenoviruses |
| Q40031348 | A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes |
| Q41813055 | A three-dimensional assay for measurement of viral-induced oncolysis |
| Q36544244 | A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth. |
| Q40347903 | Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screening. |
| Q35000513 | Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA. |
| Q36220624 | Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer |
| Q99400790 | Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes |
| Q39989453 | Adenovirus-mediated expression of SSAT inhibits colorectal cancer cell growth in vitro |
| Q40313902 | Adenovirus-mediated expression of both antisense ODC and AdoMetDC inhibited colorectal cancer cell growth in vitro |
| Q45871162 | Adenoviruses 16 and CV23 efficiently transduce human low-passage brain tumor and cancer stem cells |
| Q39673855 | Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro |
| Q36558142 | Characterization of an Oncolytic Adenovirus Vector Constructed to Target the cMet Receptor |
| Q42728981 | Co-delivery of adenovirus and carmustine by anionic liposomes with synergistic anti-tumor effects. |
| Q40440806 | Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer |
| Q45879240 | Conference report--gene therapy and lung cancer--no time to wait |
| Q45879234 | Conference report--gene therapy--quality matters |
| Q46247896 | Coxsackie- and adenovirus receptor (CAR) is expressed in lymphatic vessels in human skin and affects lymphatic endothelial cell function in vitro |
| Q24683229 | Current developments in adenovirus-based cancer gene therapy |
| Q39915885 | Differential role of alpha(v)beta(3) and alpha(v)beta(5) integrins in internalization and transduction efficacies of wild type and RGD4C fiber-modified adenoviruses |
| Q40462233 | Effect of hypoxia on Ad5 infection, transgene expression and replication. |
| Q39018330 | Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer |
| Q42255825 | Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures |
| Q35624010 | Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. |
| Q39197357 | Fiber-substituted conditionally replicating adenovirus Ad5F35 induces oncolysis of human bladder cancer cells in in vitro analysis |
| Q36226708 | Gene therapy for malignant glioma: current clinical status |
| Q38125693 | Gene therapy in oral cancer: a review |
| Q36464907 | Gene transfer approaches for gynecological diseases |
| Q34830129 | Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. |
| Q47677023 | Human dendritic cells infected with an adenoviral vector suppress proliferation of autologous and allogeneic T cells |
| Q34134316 | Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. |
| Q40624726 | In Silico Molecular Modeling and Docking Studies on Novel Mutants (E229V, H225P and D230C) of the Nucleotide-Binding Domain of Homo sapiens Hsp70. |
| Q40093470 | In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells |
| Q40026347 | Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region |
| Q38875030 | Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy |
| Q45866775 | Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. |
| Q40071407 | Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model. |
| Q37773253 | New perspectives in cancer virotherapy: bringing the immune system into play |
| Q39067827 | Novel oncolytic viral therapies in patients with thoracic malignancies |
| Q39616158 | Oncolytic adenovirus based on serotype 3. |
| Q40395130 | Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression |
| Q34405325 | Oncolytic immunotherapy: where are we clinically? |
| Q36072752 | Oncolytic viruses for cancer therapy I. Cell-external factors: virus entry and receptor interaction |
| Q37777745 | Oncolytic-adenovirus-expressed RNA interference for cancer therapy |
| Q39741908 | Recombinant baculovirus as a highly potent vector for gene therapy of human colorectal carcinoma: molecular cloning, expression, and in vitro characterization |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q27307734 | SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I |
| Q40341364 | Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells. |
| Q21144267 | Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses |
| Q39445629 | Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. |
| Q41900379 | Transposon-assisted cloning and traceless mutagenesis of adenoviruses: Development of a novel vector based on species D. |
| Q34183436 | Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. |
| Q38893420 | Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans |
| Q40111393 | Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus |
Search more.